ArticlePloS one2026
Safety and therapeutic potential evaluation of Cefotaxime plus Polymyxin B against polymyxin-carbapenem resistant Klebsiella pneumoniae in a murine model.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the toxicity and antibacterial efficacy of Cefotaxime/Polymyxin B combination (CTX/PMB) against a polymyxin-carbapenem-resistant (PC-R) Klebsiella pneumoniae strain, using a mice model. METHODS AND
resultsA single-dose toxicity assay was conducted in BALB/c mice, divided into control and CTX/PMB-treated groups receiving low, medium, or high CTX doses. Body weight, food, and water intake were monitored for 14 days. After euthanasia, organ weights and plasma biochemical markers were analyzed. Medium- and high-dose groups maintained stable weight and intake. High-dose mice exhibited reduced right kidney and liver weights and elevated urea levels. Creatinine was at the upper limit in all groups, including one control mouse. For antimicrobial efficacy, BALB/c neutropenic mice infected with PC-R K. pneumoniae K18 were assigned to naïve, mock-treated, CTX, PMB, or CTX/PMB groups. Treatments were given every 12 h, and after 24 h, blood was collected to quantify bacterial load. CTX/PMB significantly reduced blood bacterial load and improved clinical condition compared to other groups.
conclusionCTX/PMB showed therapeutic potential in treating PC-R K. pneumoniae. However higher CTX doses may potentiate PMB-associated toxicity. These findings encourage further investigation in advanced preclinical models and clinical settings to fully elucidate CTX/PMB therapeutic potential and optimize dosing regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.